Multi-Centre UK Analysis of Simultaneous Pancreas and Kidney (SPK) Transplant in Recipients With Type 2 Diabetes Mellitus

Ruth V. Owen, Harry J Carr, C. Counter, S. Tingle, Emily R. Thompson, Derek M. Manas, James A. Shaw, Colin H. Wilson, Steven A White
{"title":"Multi-Centre UK Analysis of Simultaneous Pancreas and Kidney (SPK) Transplant in Recipients With Type 2 Diabetes Mellitus","authors":"Ruth V. Owen, Harry J Carr, C. Counter, S. Tingle, Emily R. Thompson, Derek M. Manas, James A. Shaw, Colin H. Wilson, Steven A White","doi":"10.3389/ti.2023.11792","DOIUrl":null,"url":null,"abstract":"90% of the UK diabetic population are classified as T2DM. This study aims to compare outcomes after SPK transplant between recipients with T1DM or T2DM. Data on all UK SPK transplants from 2003–2019 were obtained from the NHSBT Registry (n = 2,236). Current SPK transplant selection criteria for T2DM requires insulin treatment and recipient BMI < 30 kg/m2. After exclusions (re-transplants/ambiguous type of diabetes) we had a cohort of n = 2,154. Graft (GS) and patient (PS) survival analyses were conducted using Kaplan-Meier plots and Cox-regression models. Complications were compared using chi-squared analyses. 95.6% of SPK transplants were performed in recipients with T1DM (n = 2,060). Univariate analysis showed comparable outcomes for pancreas GS at 1 year (p = 0.120), 3 years (p = 0.237), and 10 years (p = 0.196) and kidney GS at 1 year (p = 0.438), 3 years (p = 0.548), and 10 years (p = 0.947). PS was comparable at 1 year (p = 0.886) and 3 years (p = 0.237) and at 10 years (p = 0.161). Multi-variate analysis showed comparable outcomes in pancreas GS (p = 0.564, HR 1.221, 95% CI 0.619, 2.406) and PS(p = 0.556, HR 1.280, 95% CI 0.563, 2.911). Comparable rates of common complications were demonstrated. This is the largest series outside of the US evaluating outcomes after SPK transplants and shows similar outcomes between T1DM and T2DM recipients. It is hoped dissemination of this data will lead to increased referral rates and assessment of T2DM patients who could benefit from SPK transplantation.","PeriodicalId":506324,"journal":{"name":"Transplant International","volume":"13 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/ti.2023.11792","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

90% of the UK diabetic population are classified as T2DM. This study aims to compare outcomes after SPK transplant between recipients with T1DM or T2DM. Data on all UK SPK transplants from 2003–2019 were obtained from the NHSBT Registry (n = 2,236). Current SPK transplant selection criteria for T2DM requires insulin treatment and recipient BMI < 30 kg/m2. After exclusions (re-transplants/ambiguous type of diabetes) we had a cohort of n = 2,154. Graft (GS) and patient (PS) survival analyses were conducted using Kaplan-Meier plots and Cox-regression models. Complications were compared using chi-squared analyses. 95.6% of SPK transplants were performed in recipients with T1DM (n = 2,060). Univariate analysis showed comparable outcomes for pancreas GS at 1 year (p = 0.120), 3 years (p = 0.237), and 10 years (p = 0.196) and kidney GS at 1 year (p = 0.438), 3 years (p = 0.548), and 10 years (p = 0.947). PS was comparable at 1 year (p = 0.886) and 3 years (p = 0.237) and at 10 years (p = 0.161). Multi-variate analysis showed comparable outcomes in pancreas GS (p = 0.564, HR 1.221, 95% CI 0.619, 2.406) and PS(p = 0.556, HR 1.280, 95% CI 0.563, 2.911). Comparable rates of common complications were demonstrated. This is the largest series outside of the US evaluating outcomes after SPK transplants and shows similar outcomes between T1DM and T2DM recipients. It is hoped dissemination of this data will lead to increased referral rates and assessment of T2DM patients who could benefit from SPK transplantation.
英国多中心对 2 型糖尿病受体胰肾(SPK)同时移植的分析
英国 90% 的糖尿病患者被归类为 T2DM。本研究旨在比较T1DM或T2DM受者进行SPK移植后的疗效。2003-2019年英国所有SPK移植的数据均来自NHSBT登记处(n = 2,236)。目前T2DM的SPK移植选择标准要求胰岛素治疗和受者体重指数<30 kg/m2。排除(再次移植/糖尿病类型不明确)后,我们的队列中有 n = 2,154 人。使用 Kaplan-Meier 图和 Cox 回归模型对移植物(GS)和患者(PS)的存活率进行分析。并发症采用卡方分析进行比较。95.6%的SPK移植是在患有T1DM的受者中进行的(n = 2,060)。单变量分析显示,胰腺GS在1年(p = 0.120)、3年(p = 0.237)和10年(p = 0.196)时的结果与肾脏GS在1年(p = 0.438)、3年(p = 0.548)和10年(p = 0.947)时的结果相当。1年(p = 0.886)、3年(p = 0.237)和10年(p = 0.161)的PS具有可比性。多变量分析显示,胰腺GS(p = 0.564,HR 1.221,95% CI 0.619,2.406)和PS(p = 0.556,HR 1.280,95% CI 0.563,2.911)的结果相当。常见并发症的发生率相当。这是美国以外评估SPK移植后疗效的最大系列研究,显示T1DM和T2DM受者的疗效相似。希望这些数据的传播能提高转诊率,并对可能从 SPK 移植中获益的 T2DM 患者进行评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信